An airtrap for a medical or physiological fluid in one embodiment includes a conical housing having a radius that increases from its top to its bottom when the housing is positioned for operation; a medical or physiological fluid inlet located at an upper portion of the conical housing; a medical or physiological fluid outlet located at a lower portion of the conical housing, the inlet and the outlet positioned and arranged so that medical or physiological fluid spirals in an increasing arc around an inside of the conical housing downwardly from the inlet to the outlet; and a gas collection area located at an upper portion of the conical housing. In another embodiment, the airtrap is shaped like a seahorse having a head section and a tail section. Any of the airtraps herein may be used for example in blood sets, peritoneal dialysis cassette tubing, and drug delivery sets.

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

Disclosed are methods, systems, and devices for removing cytokines and other substances from blood of a subject in a closed fluid circuit. The methods, systems, and devices involve: (i) passing venous blood from the subject through a plasma separator, thereby separating the blood into blood cells and plasma; (ii) passing the plasma received from the plasma separator through an adsorption chamber located in the circuit to form processed plasma, where materials in the adsorption chamber adsorb cytokines in the plasma to form the processed plasma, and where the materials include, by weight, 50-70% activated carbon and 30-50% non-ionic resin; (iii) combining the processed plasma, received directly from the adsorption chamber, with the blood cells in a combining chamber to form processed blood, without exchanging any of the plasma for another fluid; and (iv) transfusing the processed blood from the circuit directly into the subject, where no fluid besides the subject's blood is added to the circuit before the transfusing of the processed blood into the subject is completed.

The invention relates to devices, systems, and methods for calculating a bicarbonate concentration in a fluid used in dialysis. The devices, systems, and methods can be used to calculate the bicarbonate concentration in either dialysate or blood. The invention measures the amount of carbon dioxide in both an acidified and non-acidified solution and calculates the bicarbonate concentration based on the difference in carbon dioxide concentrations.

Methods and devices for powdered sorbent regeneration of biologic fluids are disclosed. The present invention includes three novel methods, which may be used singly or in any combination, for constraining or immobilizing powders so that they can be perfused with a biological fluid or dialysate: a porous carbon block filter, a filtration bed of very fine powder, and a cone-shaped reactor.

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

The present disclosure provides cell therapy production systems that can suitably be used in a patient bedside setting. Such systems allow for direct removal of a patient's blood, automated processing to produce a cell therapy, and then infusion back into the patient, without the need to remove the system from the patient's bedside. Also provided herein are systems for production of cell therapies in a bedside setting.

The present invention relates to a method and apparatus for the isolation, modification and re-administration of a molecule or biomolecule, or a class of biomolecules, from the body fluid of a mammal via an extracorporeal closed circuit device. The device is able to capture and modify the biomolecule by the covalent or non-covalent attachment of a secondary molecule or protein, by cross-linking the captured molecule, or by altering the structure of the molecule (for example, by deglycosylation, peptide cleavage, or aggregation). The apparatus can be used to return the modified molecule or biomolecule to the mammalian subject. The device and methods may be utilized for the patient-specific diagnosis and/or treatment of a disease state which presents an associated molecule or protein in plasma or any other fluidized physiological system. The methods and apparatus may also be employed as a closed system allowing the on-line purification and/or modification of a target molecule or biomolecule from a fluid source such as a bioreactor or perfusion bioreactor.

Antiviral biomimetic polymers (ABPs) are disclosed that can be used to prevent and/or treat viral disease. The ABPs are discovered by a process involving high-throughput screening of polymer libraries using disease-relevant bioactive molecules as target molecules. ABPs can be nanoscale (termed nanoABPs) or larger. Methods are described for the preparation and use of ABPs as prophylactics and therapeutics (in vivo) and as preventative agents, for example, in personal protective equipment (ex vivo). ABPs can be used to prevent and treat viral diseases including those caused by Filoviridae.